DWS Invest CROCI Global Dividends GBP ID
Pricing frequency
Daily
Dealing cut off time
13:45
Type
SICAV
Yield
2.07%
NAV
£272.29
Income frequency
Annually
Ongoing charge
0.76%
Latest actual NAV date
13-11-2026
ISIN
LU1769943397
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/09/2026 | % of assets |
|---|---|
| CSL Ltd | 2.38 |
| Viatris Inc | 2.31 |
| Merck & Co Inc | 2.27 |
| Daiichi Sankyo Co Ltd | 2.21 |
| Gilead Sciences Inc | 2.18 |
| Pfizer Inc | 2.17 |
| Accenture PLC Class A | 2.16 |
| Takeda Pharmaceutical Co Ltd | 2.16 |
| Shionogi & Co Ltd | 2.15 |
| Astellas Pharma Inc | 2.14 |
Investment objective
This sub-fund promotes environmental and social characteristics and reports as product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability related disclosures in the financial services sector (“SFDR”). The objective of the investment policy of the fund is to achieve long term capital appreciation by investing at least 60% in large cap developed market global equities that are considered undervalued and offer comparatively high and sustainable dividend yield according to the CROCI methodology and the CROCI Global Dividends investment strategy.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.